ARS Pharmaceuticals, Inc. (SPRY) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for ARS Pharmaceuticals, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -6.70x | 127.87x | -9.60x | -9.83x | -9.50x | -1509.91x |
| P/B Ratio | 10.05x | 3.98x | 2.26x | 1.25x | -6.15x | -114.44x |
| P/S Ratio | 13.63x | 11.47x | 17392.67x | 258.99x | 34.92x | 90.16x |
| Profitability | ||||||
| Gross Margin | 75.8% | 76.9% | 100.0% | -1200.9% | 96.1% | 21.1% |
| Operating Margin | -212.9% | -3.5% | -225066.7% | -2698.8% | -353.3% | -2.6% |
| Net Margin | -203.3% | 9.0% | -181216.7% | -2635.4% | -367.7% | -6.0% |
| EBITDA Margin | -211.3% | -3.4% | -224823.3% | -2674.5% | -349.5% | -2.6% |
| Liquidity | ||||||
| Current Ratio | 7.28x | 14.26x | 96.85x | 51.01x | 7.42x | 3.21x |
| Quick Ratio | 7.06x | 14.04x | 96.85x | 51.01x | 7.42x | 3.21x |
| Leverage | ||||||
| Debt/Equity | 0.85x | 0.00x | 0.00x | 0.00x | -0.29x | -0.71x |
YoY = year-over-year change. Source: FMP..